Acadia Axes Failed Schizophrenia Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
ACP-104's Phase II demise won't dampen prospects for pimavanserin, company insists.
You may also be interested in...
Acadia Now Has The Cash To Finish Phase III On Its Own
After announcing promising Phase III data in late November, Acadia Pharmaceuticals conducted a private placement of nearly 20 million shares that will net the company $86.4 million in funds to continue running its Phase III program for pimavanserin in Parkinson’s disease psychosis.
Acadia Moving Ahead With 5HT2A Agonist In Parkinson’s Psychosis, Schizophrenia
The company is seeking to partner ACP-103 for schizophrenia following positive Phase II data.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.